Horikoshi Yuho, Suwa Junichi, Higuchi Hiroshi, Kaneko Tetsuji, Furuichi Mihoko, Aizawa Yuta, Fukuoka Kahoru, Okazaki Kaoru, Ito Kenta, Shoji Takayo
Division of Infectious Diseases, Department of Pediatrics, Tokyo Metropolitan Children's Medical Center, 2-8-29 Musashidai, Fuchu City, Tokyo, 183-8561, Japan.
Department of Pharmacy, Tokyo Metropolitan Children's Medical Center, Fuchu City, Tokyo, Japan.
Int J Infect Dis. 2017 Nov;64:69-73. doi: 10.1016/j.ijid.2017.09.012. Epub 2017 Sep 21.
The impact of pediatric antimicrobial stewardship programs (ASP) on antimicrobial resistance (AMR) remains largely unknown. This study aimed to evaluate the AMR for carbapenem of Gram-negative bacilli (GNB) and carbapenem use with infectious diseases consultation after the implementation of an ASP.
This quasi-experimental study was conducted at Tokyo Metropolitan Children's Medical Center in Japan. The pre- and post-intervention periods were April 2010 to September 2011 and October 2011 to March 2017, respectively. The pre-intervention phase consisted of consultations with the infectious diseases service alone. The ASP was implemented during the post-intervention phase. The carbapenem resistance rates of GNB were calculated. The correlation between carbapenem resistance rates and carbapenem day of therapy (DOT) was examined. The outcome metrics were compared by average length of hospitalization, all-cause mortality, and infection-related mortality.
A positive correlation was observed between the carbapenem resistance rate in Pseudomonas aeruginosa and DOT (0.76, p=0.04). The carbapenem resistance rate in P. aeruginosa (p<0.01) and DOT (p<0.01) decreased significantly in the post-intervention period. The length of hospitalization (p<0.01) and infection-related mortality (p=0.05) decreased in the post-intervention period.
A sustained ASP with additional consultation with the infectious disease service reduced carbapenem use and resistance in P. aeruginosa, leading to favorable outcomes in terms of length of hospitalization and infection-related mortality.
儿科抗菌药物管理计划(ASP)对抗菌药物耐药性(AMR)的影响在很大程度上仍不清楚。本研究旨在评估实施ASP后革兰氏阴性杆菌(GNB)对碳青霉烯类的AMR以及碳青霉烯类的使用与感染性疾病会诊情况。
这项准实验研究在日本东京都儿童医疗中心进行。干预前和干预后阶段分别为2010年4月至2011年9月和2011年10月至2017年3月。干预前阶段仅包括与感染性疾病服务部门的会诊。ASP在干预后阶段实施。计算GNB的碳青霉烯类耐药率。检查碳青霉烯类耐药率与碳青霉烯类治疗日(DOT)之间的相关性。通过平均住院时间、全因死亡率和感染相关死亡率比较结果指标。
铜绿假单胞菌的碳青霉烯类耐药率与DOT之间存在正相关(0.76,p = 0.04)。干预后阶段,铜绿假单胞菌的碳青霉烯类耐药率(p<0.01)和DOT(p<0.01)显著下降。干预后阶段住院时间(p<0.01)和感染相关死亡率(p = 0.05)下降。
持续的ASP加上与感染性疾病服务部门的额外会诊减少了铜绿假单胞菌中碳青霉烯类的使用和耐药性,在住院时间和感染相关死亡率方面产生了良好的结果。